913168-10-2

Basic information

• Product Name: Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate
• Synonyms: Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate;1H-benzo[d][1,2,3]triazol-1-yl(2-(pyridin-2-yldisulfanyl)ethyl)carbonate
• CAS NO: 913168-10-2
• Molecular Formula: C₁₄H₁₂N₄O₃S₂
• Molecular Weight: 348.40008
• Mol File: 913168-10-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 511.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.70±0.19(Predicted)
• CAS DataBase Reference: Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate(913168-10-2)
• EPA Substance Registry System: Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate(913168-10-2)

Safety Data

• Hazardous Substances Data: 913168-10-2(Hazardous Substances Data)

Usage

General Description

Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is a chemical compound with a complex structure. It contains a benzo[d][1,2,3]triazole ring with a carbonate group attached to the ethyl chain and a pyridine disulfide. It is used in chemical research and drug development due to its potential biological and pharmacological activities. The compound's intricate structure suggests that it may have specific targeting and interaction capabilities within biological systems, making it a valuable tool for studying molecular interactions and potentially serving as a lead compound for the development of new drugs. Further research is needed to fully understand the chemical properties and potential applications of this compound.

Upstream product

• 118930-99-7 2-(2-hydroxyethyl)disulfanylpyridine hydrochloride 
• 2637-34-5 2-Sulfanylpyridine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 111625-28-6 2-(2-(Pyridin-2-yl)disulfanyl)ethanol 
• 2592-95-2 benzotriazol-1-ol 
• 503-38-8 trichloromethyl chloroformate 
• 892402-96-9 (1-chloroformyloxy)ethyl 2-pyridinyl disulfide 

Downstream Products

• 1312678-90-2 everolimus (2'-pyridyldisulfanyl)ethyl carbonate 
• 1218756-66-1 C₂₇H₂₉N₁₁O₆S₂ 
• 1219142-62-7 C₃₁H₃₇N₁₁O₆S₂ 
• 1048378-93-3 C₅₉H₈₆N₂O₁₅S₂ 

Relevant articles and documents

CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER

Ligand-drug conjugates for targeted melanoma therapies are disclosed herein. A ligand is conjugated to a cytotoxic cancer drug through a cleavage linker. The ligand can bind to an overexpressed receptor on a cancer cell, resulting in selectivity. This allows the drug to enter a cancer cell selectively and release the drug within that specific cancer cell. Such therapies provide selectivity to melanoma through a ligand that targets the MC1R receptor, which is highly expressed in 80% of malignant melanomas. The ligand-drug conjugates can be used to deliver a wide range of cytotoxic cancer drugs selective to melanoma cells which may solve the drug resistance problem of melanoma in current therapies.

Novel mTOR inhibitor compounds and the use thereof

The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.

A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors

Herein, we report an alternative synthetic approach for selected 2,6,9-trisubstituted purine CDK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors. In contrast to the previously reported approaches, the desired conj